Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Peter P. Lee(City Of Hope National Medical Center), Mark M. Davis(Stanford Medicine), John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Philip D. Greenberg(University of Washington), Peter A. Savage(Howard Hughes Medical Institute), Jeffrey S. Weber(NYU Langone Health), Denise Johnson(Stanford University), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Susan M. Swetter(Stanford University), Mario Roederer(National Institutes of Health), Dirk G. Brockstedt(Rapt Therapeutics (United States)), Cassian Yee(The University of Texas MD Anderson Cancer Center)
Cited by 1,121
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k